Transumbilical Laparoendoscopic Single-site Surgery in the Treatment of 363 Patients With Gynecologic Malignant Neoplasms
10.3969/j.issn.1009-6604.2025.07.001
- VernacularTitle:经脐单孔腹腔镜技术治疗妇科恶性肿瘤363例
- Author:
Lusi DENG
1
;
Ying ZHENG
1
;
Fan YANG
1
Author Information
1. 四川大学华西第二医院妇产科 出生缺陷与相关妇儿疾病教育部重点实验室,成都 610041
- Publication Type:Journal Article
- Keywords:
Laparoscopy;
Laparoendoscopic single-site surgery;
Gynecological malignant neoplasms
- From:
Chinese Journal of Minimally Invasive Surgery
2025;25(7):385-392
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the feasibility and safety of transumbilical laparoendoscopic single-site surgery(TU-LESS)in the treatment of gynecologic malignant neoplasms.Methods The data of 363 patients with gynecologic malignant neoplas from November 2017 to October 2021 were collected for retrospective study.There were 123 cases of endometrial cancer[4 cases of robotic TU-LESS(R-TU-LESS)],211 cases of cervical cancer(16 cases of R-TU-LESS),and 29 cases of ovarian cancer(1 case of R-TU-LESS).Data collection included operation-related characteristics,postoperative rehabilitation indicators and oncological outcomes.Results ①Feasibility:the surgical conversion rate of the three groups was 3.3%(4/123),4.3%(9/211),and 6.9%(2/29),and the average operation duration was(213.8±64.3)min,(288.8±85.6)min,and(307.0±73.6)min,respectively.②Safety:the median value of blood loss during surgery of the three groups was 50(50,100)ml,100(50,200)ml,and 100(65,325)ml,the intraoperative complications rate was 3.3%(4/123),4.7%(10/211),and 17.2%(5/29),the postoperative complications rate was 7.3%(9/123),11.4%(24/211),and 17.2%(5/29),the median follow up time was 42.1(23.3,69.6)months,41.5(23.3,70.6)months,and 39.9(23.1,65.5)months,the five-year disease-free survival(DFS)was 92.3%,93.3%,and 84.4%,and the five-year overall survival(OS)was 96.8%,94.5%,and 88.5%,respectively.Conclusion TU-LESS is a safe and feasible approach for the treatment of gynecologic malignant neoplasms.
